T Batchelor

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkin's lymphoma
    T Batchelor
    Brain Tumor Center, Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Lymphoma 2:116-9; discussion 120-2. 2001
  2. ncbi request reprint Primary CNS lymphoma
    Tracy Batchelor
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 24:1281-8. 2006
  3. pmc AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
    Tracy T Batchelor
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Cancer Cell 11:83-95. 2007
  4. ncbi request reprint Neuro-oncology update: 2005
    Tracy Batchelor
    Department of Neurology, Harvard Medical School, Neurology Service and Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Curr Opin Neurol 18:631. 2005
  5. pmc Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
    Tracy T Batchelor
    Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 28:2817-23. 2010
  6. ncbi request reprint Supportive care of brain tumor patients
    Tracy T Batchelor
    Department of Neurology, Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    Hematol Oncol Clin North Am 20:1337-61. 2006
  7. ncbi request reprint Age-dependent prognostic effects of genetic alterations in glioblastoma
    Tracy T Batchelor
    Molecular Neuro oncology Laboratory, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 10:228-33. 2004
  8. ncbi request reprint Clinical trials in neuro-oncology
    T Batchelor
    Department of Neurology, Harvard Medical School, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
    Curr Opin Neurol 14:689-94. 2001
  9. ncbi request reprint Primary nervous system lymphoma
    Scott R Plotkin
    Brain Tumor Center, Cox 315, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
    Curr Treat Options Oncol 3:525-35. 2002
  10. doi request reprint Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation
    Elizabeth R Gerstner
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Neurology 70:401-2. 2008

Detail Information

Publications65

  1. ncbi request reprint High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkin's lymphoma
    T Batchelor
    Brain Tumor Center, Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Lymphoma 2:116-9; discussion 120-2. 2001
    ..These patients were treated with high-dose intravenous methotrexate alone, and a complete remission was achieved in all 4 patients...
  2. ncbi request reprint Primary CNS lymphoma
    Tracy Batchelor
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 24:1281-8. 2006
    ..The risk of neurotoxicity is lower in patients treated with chemotherapy alone...
  3. pmc AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
    Tracy T Batchelor
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Cancer Cell 11:83-95. 2007
    ..Our study provides insight into different mechanisms of action of this class of drugs in recurrent glioblastoma patients and suggests that the timing of combination therapy may be critical for optimizing activity against this tumor...
  4. ncbi request reprint Neuro-oncology update: 2005
    Tracy Batchelor
    Department of Neurology, Harvard Medical School, Neurology Service and Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Curr Opin Neurol 18:631. 2005
  5. pmc Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
    Tracy T Batchelor
    Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 28:2817-23. 2010
    ..Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in patients with recurrent glioblastoma...
  6. ncbi request reprint Supportive care of brain tumor patients
    Tracy T Batchelor
    Department of Neurology, Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    Hematol Oncol Clin North Am 20:1337-61. 2006
    ..Effective treatment is usually possible, however, and can result in an improved quality of life for these patients...
  7. ncbi request reprint Age-dependent prognostic effects of genetic alterations in glioblastoma
    Tracy T Batchelor
    Molecular Neuro oncology Laboratory, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 10:228-33. 2004
    ..Although the genetic alterations in glioblastoma have been well characterized, reports regarding their prognostic effects have been inconsistent...
  8. ncbi request reprint Clinical trials in neuro-oncology
    T Batchelor
    Department of Neurology, Harvard Medical School, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
    Curr Opin Neurol 14:689-94. 2001
    ..This review begins with enumeration of the basic principles of clinical trial design including reduction of bias and variability, and concludes with a review of study design factors of particular relevance for neuro-oncology...
  9. ncbi request reprint Primary nervous system lymphoma
    Scott R Plotkin
    Brain Tumor Center, Cox 315, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
    Curr Treat Options Oncol 3:525-35. 2002
    ..Given the rarity of this tumor, patients with PNSL should be referred to tertiary cancer centers where ongoing clinical trials are underway to identify the optimal treatment of PNSL...
  10. doi request reprint Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation
    Elizabeth R Gerstner
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Neurology 70:401-2. 2008
  11. pmc Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice
    Walid S Kamoun
    Edwin L Steele Laboratory, Department of Radiation Oncology, Stephen E and Catherine Pappas Center for Neuro Oncology, and AA Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 27:2542-52. 2009
    ..Our goal was to determine whether alleviation of edema by anti-VEGF agents alone could increase survival in mice...
  12. pmc Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults
    Santosh Kesari
    Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, 44 Binney St, SW430D, Boston, MA 02115, USA
    Neuro Oncol 10:300-8. 2008
    ..07) and PFS (p=0.09). The addition of celecoxib and thalidomide to adjuvant temozolomide was well tolerated but did not meet the primary end point of improvement of 4-month PFS from study enrollment...
  13. pmc A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients
    A Gregory Sorensen
    A A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Res 69:5296-300. 2009
    ..54; P = 0.004) and progression-free survival (rho = 0.6; P = 0.001). The vascular normalization index described here should be validated in randomized clinical trials...
  14. doi request reprint Angiogenesis as a therapeutic target in malignant gliomas
    Andrew S Chi
    Department of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Oncologist 14:621-36. 2009
    ..Although challenges remain with this approach, ongoing studies may improve upon the promising initial benefits already observed in GBM patients...
  15. ncbi request reprint Genetic analyses for predictors of radiation response in glioblastoma
    Helen A Shih
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Int J Radiat Oncol Biol Phys 63:704-10. 2005
    ..It has been previously reported that epidermal growth factor receptor (EGFR) gene amplification and TP53 mutation correlate with the response to RT in patients with glioblastoma...
  16. ncbi request reprint Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma
    Paul L Nguyen
    Massachusetts General Hospital, Department of Radiation Oncology, 100 Blossom St, Boston, MA 02114, USA
    J Clin Oncol 23:1507-13. 2005
    ..This study evaluates the efficacy and toxicity of whole-brain radiation therapy (WBRT) as salvage therapy for immunocompetent patients who failed initial high-dose methotrexate for primary CNS lymphoma (PCNSL)...
  17. pmc Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults
    Santosh Kesari
    Center for Neuro Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Neuro Oncol 9:354-63. 2007
    ..While metronomic chemotherapy may not be useful in patients with advanced disease, further studies using metronomic chemotherapy combined with more potent antiangiogenic agents in patients with less advanced disease may be warranted...
  18. ncbi request reprint Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival
    Masahiro Mizoguchi
    Molecular Pathology Unit and Molecular Neuro Oncology Laboratory, Department of Pathology, Cancer Center and Neurosurgical Service, Massachusetts General Hospital and Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA
    J Neuropathol Exp Neurol 65:1181-8. 2006
    ..Taken together, these findings begin to elucidate the interrelationship between these signaling pathways in astrocytic gliomas in vivo...
  19. doi request reprint Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma
    Jan Drappatz
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 78:85-90. 2010
    ..We conducted a Phase I study of vandetanib, an inhibitor of vascular endothelial growth factor receptor 2 and epidermal growth factor receptor, in patients with newly diagnosed GBM combined with RT and temozolomide (TMZ)...
  20. ncbi request reprint Angiogenesis in brain tumours
    Rakesh K Jain
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, Massachusetts 02114, USA
    Nat Rev Neurosci 8:610-22. 2007
    ..This creates a window of opportunity for optimally combining chemotherapeutics and radiation...
  21. pmc Genome-wide comparison of paired fresh frozen and formalin-fixed paraffin-embedded gliomas by custom BAC and oligonucleotide array comparative genomic hybridization: facilitating analysis of archival gliomas
    Gayatry Mohapatra
    Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Acta Neuropathol 121:529-43. 2011
    ..In combination, these advances should facilitate genome-wide analysis of rare, small and/or histologically heterogeneous gliomas from FFPE tissues...
  22. pmc The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma
    David J Sher
    Harvard Radiation Oncology Program, Boston, MA, USA
    J Neurooncol 88:43-50. 2008
    ..We sought to determine the relative contribution of concomitant temozolomide in patients treated by concurrent and adjuvant TMZ versus adjuvant TMZ alone in the setting of newly diagnosed GBM...
  23. doi request reprint VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer
    Elizabeth R Gerstner
    Department of Neurology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Nat Rev Clin Oncol 6:229-36. 2009
    ..Anti-VEGF agents might also be useful in other cancer-related conditions that increase vascular permeability, such as malignant pleural effusions or ascites...
  24. ncbi request reprint Anti-vascular endothelial growth factor therapy for malignant glioma
    Elizabeth R Gerstner
    Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA
    Curr Neurol Neurosci Rep 9:254-62. 2009
    ..However, because most patients eventually relapse, more work is needed to understand mechanisms of disease escape, including vascular co-option of native brain blood vessels...
  25. pmc High-dose methotrexate for elderly patients with primary CNS lymphoma
    Jay Jiguang Zhu
    Department of Neurology, Tufts New England Medical Center, Boston, MA, USA
    Neuro Oncol 11:211-5. 2009
    ..High-dose MTX should be considered as a feasible treatment option in elderly patients with PCNSL...
  26. ncbi request reprint Leptomeningeal neoplasms
    Jan Drappatz
    Jan Drappatz, MD Harvard Medical School, Department of Neurology, Brigham and Women s Hospital and Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, 44 Binney Street SW 430, Boston, MA 02115, USA
    Curr Treat Options Neurol 9:283-93. 2007
    ..There is hope that progress in diagnostic modalities and the development of more effective intrathecal antineoplastic drugs may decrease neurologic morbidity and improve quality of life and survival...
  27. pmc CNS Hodgkin lymphoma
    Elizabeth R Gerstner
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Blood 112:1658-61. 2008
    ....
  28. pmc Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment
    Daniel P Cahill
    Molecular Pathology Unit, Neurosurgical Service, Brain Tumor Center, and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Clin Cancer Res 13:2038-45. 2007
    ..However, the extent of involvement of MSH6 in glioblastoma is unknown. We sought to determine the overall frequency and clinical relevance of MSH6 alterations in glioblastomas...
  29. ncbi request reprint Treatment of relapsed central nervous system lymphoma with high-dose methotrexate
    Scott R Plotkin
    Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 10:5643-6. 2004
    ..The optimal management of these patients has not been determined. We performed a multicenter, retrospective study of high-dose methotrexate in patients with relapsed central nervous system lymphoma...
  30. doi request reprint Imaging and response criteria in gliomas
    Elizabeth R Gerstner
    Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Curr Opin Oncol 22:598-603. 2010
    ..These new techniques are increasingly being incorporated into clinical trials and even into clinical practice. Therefore, it is important to be familiar with the available imaging techniques and their potential uses versus limitations...
  31. pmc Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib
    Elizabeth R Gerstner
    Departments of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Neuro Oncol 12:466-72. 2010
    ..ADC maps can be used to suggest regions of infiltrative tumor cells with anti-VEGF therapy and should be validated in future studies...
  32. doi request reprint Primary central nervous system lymphoma
    Elizabeth R Gerstner
    Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA
    Arch Neurol 67:291-7. 2010
    ..Unfortunately, although durable remissions may be achieved for some patients with PCNSL, the tumor relapses in most cases. In this review, we will focus on PCNSL in the immunocompetent host...
  33. doi request reprint Vascular endothelial growth factor inhibitors in malignant gliomas
    Priscilla K Brastianos
    Stephen E and Catherine Pappas Center for Neuro Oncology, Department of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Target Oncol 5:167-74. 2010
    ..Unfortunately, antiangiogenic treatment inevitably fails in most patients. Further studies are needed to understand the molecular pathways that enable a tumor to evade antiangiogenic therapy...
  34. ncbi request reprint BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma
    Kristina M Braaten
    Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Clin Cancer Res 9:1063-9. 2003
    ..v. high-dose methotrexate therapy...
  35. ncbi request reprint High-dose methotrexate for intraocular lymphoma
    Tracy T Batchelor
    Massachusetts General Hospital Brain Tumor Center and Neurology Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Cancer Res 9:711-5. 2003
    ..We also sought to determine whether micromolar levels of MTX could be achieved in the aqueous and vitreous humor of the eye after i.v. administration of the drug...
  36. ncbi request reprint Peripheral and cranial nerve sheath tumors
    Maciej M Mrugala
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Curr Opin Neurol 18:604-10. 2005
    ..Vestibular schwannomas, neurogenetic syndromes such as schwannomatosis and multiple isolated neurofibromas, and malignant peripheral nerve sheath tumors are covered in this review...
  37. ncbi request reprint Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma
    Manish Aghi
    Neurosurgical Service, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    Clin Cancer Res 11:8600-5. 2005
    ..EGFR overexpression correlates in experimental gliomas with increased angiogenesis, edema, and invasion. No radiographic predictors of molecular glioblastoma subtype are known...
  38. pmc Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma
    Jörg Dietrich
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Expert Opin Investig Drugs 18:1549-57. 2009
    ..Treatment strategies targeting angiogenesis have revealed promising results in preclinical studies and early clinical trials in patients with glioblastomas...
  39. doi request reprint Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients
    Scott R Plotkin
    Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, U S A
    Otol Neurotol 31:1135-43. 2010
    ..We sought to determine the activity of erlotinib for progressive vestibular schwannoma (VS) associated with neurofibromatosis 2 (NF2)...
  40. doi request reprint Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas
    Elizabeth R Gerstner
    Department of Neurology, Division of Neuro Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Curr Opin Neurol 21:728-35. 2008
    ..This review will summarize new neuroimaging techniques, particularly MRI and PET imaging, that can be used to assess brain tumor growth and angiogenesis...
  41. doi request reprint A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme
    Jan Drappatz
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 73:222-7. 2009
    ....
  42. pmc Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11
    Tracy T Batchelor
    Brain Tumor Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Neuro Oncol 6:21-7. 2004
    ..Irinotecan had minimal efficacy in this cohort of 18 patients with recurrent malignant glioma. Toxicity was significant but similar to that reported in other patient populations...
  43. ncbi request reprint Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 1-2005. A 35-year-old woman with difficulty walking, headache, and nausea
    Tracy T Batchelor
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, USA
    N Engl J Med 352:185-94. 2005
  44. pmc Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate
    April F Eichler
    Pappas Center for Neuro Oncology, Boston, MA 02114, USA
    Neuro Oncol 9:373-7. 2007
    ..The absence of vascular or perfusion abnormalities suggests that transient cytotoxic edema in white matter may explain the syndrome of subacute MTX neurotoxicity...
  45. pmc VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects
    Dan G Duda
    Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, COX 734, Boston, MA 02114, USA
    Trends Mol Med 13:223-30. 2007
    ....
  46. pmc Biomarkers of response and resistance to antiangiogenic therapy
    Rakesh K Jain
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Nat Rev Clin Oncol 6:327-38. 2009
    ....
  47. ncbi request reprint The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride
    Stuart A Grossman
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231 1000, and Massachusetts General Hospital, Boston, USA
    Clin Cancer Res 12:5174-81. 2006
    ..This study was conducted to determine if the maximum tolerated dose and pharmacokinetics of PCB are affected by the concurrent use of enzyme-inducing antiseizure drugs (EIASD)...
  48. ncbi request reprint Antiangiogenic agents for the treatment of glioblastoma
    Elizabeth R Gerstner
    1Massachusetts General Hospital Cancer Center and Harvard Medical School, Department of Neurology, Boston, Massachusetts, USA
    Expert Opin Investig Drugs 16:1895-908. 2007
    ..It seems likely that a combination of antiangiogenesis agents with other cytotoxic therapies will be required to achieve maximal efficacy...
  49. doi request reprint Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report
    S A Grimm
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neurology 71:1355-60. 2008
    ..To describe the demographics, diagnostic details, therapeutic management, and outcome in patients with primary CNS lymphoma (PCNSL) with ocular involvement...
  50. ncbi request reprint Insights into the biology of primary central nervous system lymphoma
    Maciej M Mrugala
    Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Curr Oncol Rep 11:73-80. 2009
    ..This review discusses recent advances in PCNSL biology, including immunologic and genetic risk factors, and focuses on the molecular alterations important in central nervous system lymphomagenesis...
  51. doi request reprint Response criteria for glioma
    A Gregory Sorensen
    Harvard Medical School, Boston, MA, USA
    Nat Clin Pract Oncol 5:634-44. 2008
    ....
  52. ncbi request reprint YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas
    Catherine L Nutt
    Molecular Neuro Oncology Laboratory and Molecular Pathology Unit, Department of Pathology, Massachusetts General Hospital, 149 13th Street, Charlestown, MA 02129, USA
    Clin Cancer Res 11:2258-64. 2005
    ..Moreover, a combination of YKL-40 and glial fibrillary acidic protein immunohistochemistry afforded even greater diagnostic accuracy in anaplastic oligodendrogliomas...
  53. pmc Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas
    Gaurav D Shah
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Neuro Oncol 8:38-46. 2006
    ..Thus, linear methods are comparable to volumetric methods, but simpler to implement for routine clinical use and for designing clinical trials of brain tumors...
  54. ncbi request reprint Gene expression-based classification of malignant gliomas correlates better with survival than histological classification
    Catherine L Nutt
    Department of Pathology and Neurosurgical Service, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 63:1602-7. 2003
    ..These data suggest that class prediction models, based on defined molecular profiles, classify diagnostically challenging malignant gliomas in a manner that better correlates with clinical outcome than does standard pathology...
  55. ncbi request reprint VEGF inhibitors in brain tumors
    Priscilla K Brastianos
    Department of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, Massachusetts General Hospital, Boston, 02114, USA
    Clin Adv Hematol Oncol 7:753-60, 768. 2009
    ..Unfortunately, treatment inevitably fails. Further studies are needed to understand mechanisms of tumor resistance and to identify other therapeutic targets that mediate angiogenesis...
  56. ncbi request reprint Primary central nervous system lymphoma: presentation, diagnosis and staging
    April F Eichler
    Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Neurosurg Focus 21:E15. 2006
    ..Testicular ultrasonography studies should be considered in men. In patients who cannot undergo LP or in those with evidence of spinal cord dysfunction, contrast-enhanced MR imaging of the entire spine should be considered...
  57. ncbi request reprint Malignant peripheral nerve sheath tumor: the clinical spectrum and outcome of treatment
    Joachim M Baehring
    Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Neurology 61:696-8. 2003
    ..Presented is a series of 54 patients with MPNST seen at a single institution over a 10-year period. In this series, tumor diameter of <5 cm, gross total resection of the tumor, and younger age were favorable prognostic variables...
  58. ncbi request reprint Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:5034-43. 2005
    ..We hope that these guidelines will improve communication among investigators and comparability among clinical trials in a way that will allow us to develop better therapies for patients...
  59. pmc Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: case study
    Alfredo D Voloschin
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Neuro Oncol 7:97-100. 2005
    ..This treatment strategy, although common in the treatment of other solid tumors, is rarely utilized in adult neuro-oncology and raises another potential role for chromosome testing in oligodendroglial tumor management...
  60. ncbi request reprint Leptomeningeal metastases
    Santosh Kesari
    Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Neurol Clin 21:25-66. 2003
    ..This may provide an opportunity for effective intervention that can improve quality of life, prevent further neurologic deterioration and, for a subset of patients, improve survival...
  61. pmc Statistical considerations for immunohistochemistry panel development after gene expression profiling of human cancers
    Rebecca A Betensky
    Department of Biostatistics, Harvard School of Public Health, 655 Huntington Ave, Boston, Massachusetts 02115, USA
    J Mol Diagn 7:276-82. 2005
    ..Simulation approaches for computing power and sample size that are based on existing gene expression data provide a powerful tool for efficient design of follow-up genomic studies...
  62. pmc Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy
    David A Reardon
    Duke University Medical Center, Neuro Oncology Program, Department of Surgery, Division of Neurosurgery, 047 Baker House, Box 3624, Durham, North Carolina 27710, USA
    Expert Opin Biol Ther 8:541-53. 2008
    ..Malignant gliomas are amongst the most angiogenic of cancers, and VEGF is the dominant angiogenic mediator in these tumors...
  63. ncbi request reprint International study on low-grade primary central nervous system lymphoma
    Kristoph Jahnke
    Department of Hematology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Ann Neurol 59:755-62. 2006
    ..The aim of this study was to characterize the clinical presentation, course, and outcome of low-grade primary central nervous system lymphoma...
  64. ncbi request reprint A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy
    Chris Hunter
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Cancer Res 66:3987-91. 2006
    ..These observations highlight the potential of large scale sequencing for revealing and elucidating mutagenic processes operative in individual human cancers...
  65. ncbi request reprint Reversible posterior leukoencephalopathy syndrome
    Andrew D Norden
    Onkologie 30:90-1. 2007

Research Grants12

  1. A Phase 2 study of AZD2171 in Recurrent Glioblastoma
    Tracy Batchelor; Fiscal Year: 2006
    ..Incorporation of these correlative techniques into this phase 2 study represent unique strengths of our institution and will enhance our ability to assess the potential efficacy of AZD2171 in a multidimensional manner. ..
  2. AZD2171 and chemoradiation for newly diagnosed glioblastoma
    Tracy Batchelor; Fiscal Year: 2009
    ..In Aim 3 we will continue to explore the potential utility of tumor and serial blood biomarkers, including bFGF, SDF1 and CECs, as predictors of tumor response and patient outcome in the newly diagnosed GM population. ..
  3. AZD2171 and chemoradiation for newly diagnosed glioblastoma
    Tracy Batchelor; Fiscal Year: 2007
    ..In Aim 3 we will continue to explore the potential utility of tumor and serial blood biomarkers, including bFGF, SDF1 and CECs, as predictors of tumor response and patient outcome in the newly diagnosed GM population. ..
  4. Annual Primary CNS Lymphoma Collaborative Group Meeting
    Tracy Batchelor; Fiscal Year: 2007
    ..Although the group has existed for only 3 years it have fostered international collaboration across multiple disciplines on an unprecedented scale and has had an impact on PCNSL research and clinical care. ..
  5. Clinical and Molecular Studies of Novel Therapeutics in Malignant Brain Tumors
    Tracy Batchelor; Fiscal Year: 2007
    ....
  6. NABTT-New Approaches to Brain Tumor Therapy (CNSC)
    Tracy Batchelor; Fiscal Year: 2007
    ....
  7. AZD2171 and chemoradiation for newly diagnosed glioblastoma
    Tracy T Batchelor; Fiscal Year: 2010
    ..In Aim 3 we will continue to explore the potential utility of tumor and serial blood biomarkers, including bFGF, SDF1 and CECs, as predictors of tumor response and patient outcome in the newly diagnosed GM population. ..